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ABSTRACT
A new edition of the World Health Organiza-
tion (WHO) Histological classification of
tumours of the hypopharynx, larynx, trachea
and parapharyngeal space was published in
2017. We have considered this classification
regarding laryngeal neoplasms and discuss the
grounds for said revision. Many of the laryngeal
neoplasms described in the literature and in the
previous WHO edition from 2005 have been
omitted from this current revision. Many are
described elsewhere in the book but it may give
the new generation of pathologists/surgeons/
oncologists the false impression that these
tumour entities do not exist in the larynx.
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INTRODUCTION
While the crafting of a taxonomy scheme for
laryngeal tumours might not seem to be so
critical an endeavour, a well-constructed classi-
fication scheme actually serves as an essential
foundation, allowing surgeons, pathologists
and oncologists to use the same language for
clarity and precision. As such, the classification
of tumours is of considerable importance, and
many attempts have been made to correlate the
type of neoplasm with its biological behaviour.
There are clinical, topographical and staging
classifications and those based on the histolog-
ical features of the individual neoplasms. The
internationally applied TNM staging system is
based on the anatomical extent of the respec-
tive tumours, but the histological features have
been largely omitted. Early classifications were
incomplete and too simple, only including a
few types of malignant tumours, such as squa-
mous cell carcinoma, undifferentiated carci-
noma, adenocarcinoma and sarcomas.
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Histological classification of laryngeal neo-
plasms is of essential relevance to treatment
planning and evaluation of prognosis but the
frequently changing terminology may lead to
misunderstandings and even mistakes.
The earliest tumour classification schemes
relied upon the gross and/or light microscopic
features of different tumour types. Presently,
those classic gross and light microscopic differ-
entiating features are being supplemented, or
even replaced, by molecular features of the
tumours themselves [1, 2].
In an early attempt at standardizing the
nomenclature of laryngeal tumours, the World
Health Organization (WHO) published its His-
tological Typing of Upper Respiratory Tract
Tumours (which included the larynx) in 1978
[3]. This classification was the result of a team
effort by Drs. Shanmugaratnam and Sobin and
pathologists from eight countries. The first
version of this WHO classification is summa-
rized in Table 1.
The WHO classification of upper respiratory
tract and ear tumours [3] was reviewed by the
following experts:
K. Shanmugaratnam (Singapore), L. H. Sobin
(USA), L. Barnes (USA), A. Cardesa (Spain), A.
Ferlito (Italy), I. Friedmann (England), D.
K. Heffner (USA), H.B. Hellquist (Sweden), V.
J. Hyams (USA), G.R.F. Krueger (Germany), C.
Micheau (France) and A. Nascimento (Brazil).
Several of these experts met in Dublin in 1988
and an amply illustrated, revised and updated
second edition of the classification was pub-
lished in 1991 [4] (Table 2).
In 2005 a third updated edition of the WHO
Classification of Tumours was published, enti-
tled Pathology and Genetics of Head and Neck
Tumours [5]. The larynx was included within
Chapter 3 and was entitled ‘‘Hypopharynx, lar-
ynx and trachea’’ containing the following sec-
tions (Table 3).
A 4th edition WHO Classification of
Tumours, entitled Pathology and Genetics of
Head and Neck Tumours, was published in 2017
[6]. The larynx was also included in Chapter 3,
now entitled ‘‘Tumours of the hypopharynx,
larynx, trachea and parapharyngeal space’’
(Table 4).
Table 1 Histological typing of laryngeal tumours (1978)
Epithelial tumours
Benign
Squamous cell papilloma/papillomatosis
Oxyphilic adenoma (oncocytoma)
Others
Malignant
Carcinoma in situ (intraepithelial carcinoma)
Squamous cell carcinoma
Verrucous (squamous) carcinoma
Spindle cell (squamous) carcinoma
Adenocarcinoma
Adenoid cystic carcinoma
Carcinoid tumour
Others
Undifferentiated carcinoma
Soft tissue tumours
Benign
Lipoma
Haemangioma
Leiomyoma
Rhabdomyoma
Granular cell tumour
Neurofibroma
Neurilemmoma (schwannoma)
Paraganglioma (chemodectoma)
Others
Malignant
Fibrosarcoma
Rhabdomyosarcoma
Angiosarcoma
Kaposi’s sarcoma
Others
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Compliance with Ethics Guidelines
This article is based on the previously published
WHO histological classifications and so does
not involve any new studies of human or ani-
mal subjects performed by any of the authors.
CONSIDERATIONS
The application of immunohistochemical
methods, with an ever-increasing arsenal of
antibodies and recently developed molecular
biology techniques, will obviously enable a
more accurate identification and therefore a
more reliable classification of neoplasms of the
larynx. In the latest 2017 WHO Classification of
Head and Neck Tumours [6], many of the
laryngeal neoplasms described in the literature
have been omitted. For example, only three
salivary gland tumours are described, and acinic
cell, salivary duct and myoepithelial carcinomas
were not included. Similarly, unusual and rare
tumours, such as NUT (nuclear protein in testis)
midline carcinoma, synovial sarcoma, alveolar
soft sarcoma and intestinal-type adenocarci-
noma, are also not listed [7]. Therefore, one has
to refer to the earlier versions of the WHO
Classification (2nd edition 1991 and 3rd edition
Table 1 continued
Tumours of bone and cartilage
Benign
Chondroma
Others
Malignant
Chondrosarcoma
Others
Tumours of lymphoid and haemopoietic tissues
Miscellaneous tumours
Secondary tumours
Unclassified tumours
Table 2 Histological typing of laryngeal tumours (1991)
Epithelial tumours and precancerous lesions
Benign
Papilloma
Papillomatosis
Pleomorphic adenomaa
Basal cell (basaloid) adenomaa
Dysplasia and carcinoma in situ
Squamous cell dysplasia
Mild dysplasia
Moderate dysplasia
Severe dysplasia
Carcinoma in situ
Malignant
Squamous cell carcinoma
Verrucous squamous cell carcinoma
Spindle cell carcinoma
Adenoid squamous cell carcinomaa
Basaloid squamous cell carcinomaa
Adenocarcinoma
Acinic cell carcinomaa
Mucoepidermoid carcinomaa
Adenoid cystic carcinoma
Carcinoma in pleomorphic adenomaa
Epithelial-myoepithelial carcinomaa
Clear cell carcinomaa
Adenosquamous carcinomaa
Giant cell carcinomaa
Salivary duct carcinomaa
Carcinoid tumour
Atypical carcinoid tumoura
Small cell carcinomaa
Lymphoepithelial carcinomaa
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2005) to obtain a comprehensive view of the
neoplasms that have been described in the
larynx.
The histological classification is intended to
facilitate the comparison of results in various
fields of oncology and should be useful to
pathologists, laryngologists, radiotherapists and
oncologists as well as epidemiologists. A histo-
logical classification of neoplasms is extremely
important for establishing a reliable prognosis,
and this classification forms the foundation for
appropriate clinical management of patients
with laryngeal tumours.
Establishing the phenotype gives us a quali-
tative diagnosis of the disease. Different phe-
notypes have different biological behaviours, so
only similar histopathological tumour types
should be compared for their prognostic
implications.
Specific histological types also give an indi-
cation of potential prognostic features. For
example, small cell neuroendocrine carcinoma
metastasizes more frequently than squamous
cell carcinoma, which is in turn more aggres-
sive than verrucous squamous cell carcinoma.
These differences are further evidenced by the
differing survival rates. The 5-year survival
rates are approximately 68% for squamous cell
carcinoma of the larynx [8] and 5% for small
Table 2 continued
Soft tissue tumours
Benign
Aggressive fibromatosisa
Myxomaa
Fibrous histiocytomaa
Lipoma
Leiomyoma
Rhabdomyoma
Haemangioma
Haemangiopericytomaa
Lymphangiomaa
Neurilemmoma
Neurofibroma
Granular cell tumour
Paraganglioma
Malignant
Fibrosarcoma
Malignant fibrous histiocytomaa
Liposarcomaa
Leiomyosarcomaa
Rhabdomyosarcoma
Angiosarcoma
Kaposi’s sarcoma
Malignant haemangiopericytomaa
Malignant nerve sheath tumoura
Alveolar soft part sarcomaa
Synovial sarcomaa
Ewing sarcomaa
Tumours of bone and cartilage
Benign
Chondroma
Malignant
Chondrosarcoma
Table 2 continued
Osteosarcomaa
Malignant lymphomas
Miscellaneous tumours
Benign
Mature teratomaa
Malignant
Malignant melanomaa
Malignant germ cell tumoursa
Secondary tumours
Unclassified tumours
a Oncotypes new to the second edition
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cell neuroendocrine carcinoma [9], considering
all stages of the disease. Taking squamous cell
carcinoma as a yardstick for comparison, ver-
rucous squamous cell carcinoma, low-grade
mucoepidermoid carcinoma, well-differenti-
ated neuroendocrine carcinoma and chon-
drosarcoma all have a more favourable
prognosis, whereas poorly differentiated neu-
roendocrine carcinoma (both small and large
cell neuroendocrine carcinoma), moderately
differentiated neuroendocrine carcinoma, NUT
midline carcinoma and basaloid squamous
carcinoma are likely to have a less favourable
outcome.
If the histological type is properly identified,
then specific and personalized tumour treat-
ment protocols can be implemented. The phe-
notype should therefore be considered the most
important factor in determining therapeutic
decisions [10, 11]. In conclusion, confirming
both the histological diagnosis and clinical
characteristics of every tumour will form the
basis for accurate, personalized and effective
treatment planning.
Table 3 Histological typing of laryngeal tumours (2005)
Malignant epithelial tumours
Squamous cell carcinoma
Verrucous carcinoma
Basaloid squamous cell carcinoma
Papillary squamous cell carcinoma
Spindle cell carcinoma
Acantholytic squamous cell carcinoma
Adenosquamous carcinoma
Lymphoepithelial carcinoma
Giant cell carcinoma
Malignant salivary gland-type tumours
Neuroendocrine tumours
Carcinoid
Atypical carcinoid
Small cell carcinoma, neuroendocrine type
Combines small cell carcinoma, neuroendocrine type,
with non-small cell carcinoma (squamous cell
carcinoma, adenocarcinoma, etc.)
Paraganglioma
Epithelial precursor lesions
Benign epithelial tumours
Papilloma/papillomatosis
Benign salivary gland-type tumours
Malignant soft tissue tumours
Fibrosarcoma
Malignant fibrous histiocytoma (MFH)
Liposarcoma
Leomyosarcoma
Rhabdomyosarcoma
Kaposi’s sarcoma
Peripheral nerve sheath tumour (PNST)
Synovial sarcoma
Inflammatory myofibroblastic tumour
Benign soft tissue tumours
Table 3 continued
Lipoma
Leyomyoma
Haemangioma and lymphangioma
Granular cell tumour
Haematolymphoid tumours
Non-Hodgkin lymphoma
Plasmacytoma
Tumours of bone and cartilage
Chondrosarcoma
Osteosarcoma
Chondroma
Giant cell tumour
Mucosal malignant melanoma
Secondary tumours
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